Kirk, Allan D <br/><br/>
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).  [electronic resource] 

 -  Transplantation  Jul 2003 
 - 120-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0041-1337 
<br/><br/><label>Standard No.: </label>10.1097/01.TP.0000071362.99021.D9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neoplasm--therapeutic use<br/>Black People<br/>Female<br/>Follow-Up Studies<br/>Graft Rejection--epidemiology<br/>Graft Survival--drug effects<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Kidney Transplantation--immunology<br/>Lymph Nodes--immunology<br/>Lymphocyte Depletion<br/>Male<br/>Middle Aged<br/>T-Lymphocytes--immunology<br/>Time Factors<br/>Transplantation, Homologous<br/>United States<br/>White People<br/>Black or African American